PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
HOME > BUSINESS
BUSINESS
- Sato, Fuso to Copromote Emla Cream for Dialysis Patients
September 6, 2016
- Hisamitsu Starts PIII Trial of Transdermal Schizophrenia Treatment in US
September 6, 2016
- Celgene Seeks Japan Approval of Romidepsin for PTCL
September 6, 2016
- Merck Ditches Osteoporosis Med Odanacatib from Global Pipelines
September 6, 2016
- Sanofi’s PCSK9 Inhibitor Praluent Now Available in Japan
September 6, 2016
- Shionogi Takes Osaka Tax Bureau to Court
September 5, 2016
- Takeda to Develop Zika Vaccine with US Funding
September 5, 2016
- MSD Paid 15.2 Billion Yen to Doctors, Medical Institutions in 2015
September 5, 2016
- Oncolys to Evaluate Oncolytic Virus in Combination with Immune Checkpoint Inhibitors; Interim Results Expected in 2017
September 5, 2016
- Nippon Kayaku Seeks Add’l Dosage for Remicade Biosimilar in Psoriasis
September 2, 2016
- Takeda Kicks Off Global Observation Study for Multiple Myeloma
September 2, 2016
- Lilly, Osaka Univ. Join Forces on Obesity Research
September 2, 2016
- Chugai Transfers Marketing Authorization for Vesanoid to Fuji Pharma
September 2, 2016
- Sunovion to Acquire Canadian CNS Biotech: Sumitomo Dainippon
September 2, 2016
- Kipres/Singulair AG Hits Shelves in Japan: Kyorin Holdings
September 2, 2016
- Sandoz Taps Jason Hoffe as New Japan Head
September 2, 2016
- Otsuka, RIKEN Open Collaborative Research Center to Promote Regenerative Medicine
September 2, 2016
- Takecab Most Heavily Pitched Drug in July: Anterio
September 1, 2016
- Sovaldi Filed in Japan for All Hep C Genotypes Excluding Genotype 1: Gilead
September 1, 2016
- Pfizer Files Xalkori for ROS1-Positive Lung Cancer in Japan
September 1, 2016
ページ
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Global drug makers are forging ahead with therapies targeting lipoprotein(a), or Lp(a), a promising new approach to reducing cardiovascular risks.…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…